Business Context and Reporting Period
Company: Tango Therapeutics, Inc. (TNGX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Tango is a precision oncology company focused on developing targeted therapies for genetically defined cancers using synthetic lethality. The company has no products approved for commercial sale and has not generated revenue from product sales. Its primary assets are clinical-stage product candidates, including vopimetostat (TNG462) and TNG456 (PRMT5 inhibitors), TNG260 (CoREST inhibitor), and TNG961 (HBS1L degrader).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $62,384 | $42,069 |
| Net Loss | $(101,594) | $(130,302) |
| Research & Development Expenses | $132,165 | $143,918 |
| General & Administrative Expenses | $41,508 | $43,746 |
| Cash, Cash Equivalents & Marketable Securities | $343,100 | $257,900 |
| Accumulated Deficit | $(603,152) | $(501,558) |
| Net Cash Used in Operating Activities | $(138,886) | $(131,501) |
Note: Revenue is derived entirely from collaboration agreements, primarily with Gilead Sciences, Inc.
Material Changes vs. Prior Period
- Revenue Increase: Total revenue increased by $20.3 million (48%) to $62.4 million. This was driven by the recognition of $53.8 million in previously deferred revenue following the mutual truncation of the research term in the Gilead collaboration agreement in August 2025. License revenue, which was $12.1 million in 2024, was $0 in 2025.
- Reduced Net Loss: Net loss decreased by $28.7 million to $101.6 million, primarily due to the revenue recognition described above and a reduction in operating expenses.
- R&D Expense Reduction: R&D expenses decreased by $11.7 million to $132.2 million. This decrease was mainly due to the discontinuation of the TNG908 and TNG348 clinical programs and lower discovery costs, partially offset by increased spending on vopimetostat, TNG456, and TNG961.
- Liquidity Position: Cash and marketable securities increased by approximately $85 million to $343.1 million, bolstered by a $225.0 million equity offering in October 2025 and proceeds from an "at-the-market" offering program.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($343.1 million as of Dec 31, 2025) to fund operating expenses and capital expenditures into 2028.
- Clinical Milestones (2026):
- Vopimetostat: Planned initiation of a pivotal Phase 3 trial in second-line MTAP-deleted pancreatic cancer. Anticipated safety and efficacy updates for the lung cancer cohort and the combination trial with Revolution Medicines' RAS inhibitors.
- TNG456: Anticipated safety and efficacy update for the Phase 1/2 trial in glioblastoma (GBM).
- TNG260: Dose expansion ongoing for STK11 mutant/KRAS wild-type NSCLC.
- Collaborations: Entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with Erasca, Inc. in March 2026 to evaluate vopimetostat in combination with Erasca's pan-RAS molecular glue.
Material Risks and Contingencies
- Capital Requirements: The company expects to continue incurring significant losses and will need to raise substantial additional funding in the future. Failure to raise capital could force delays or elimination of product development programs.
- Supply Chain Concentration: The company relies on a single supplier (an affiliate of WuXi AppTec) for the active pharmaceutical ingredient (API) for all clinical-stage product candidates. Proposed U.S. Congressional legislation could restrict business with WuXi AppTec, posing a significant supply risk.
- Development Risk: The company has never successfully completed a clinical trial. Programs are in early stages (Phase 1/2), and there is no assurance of regulatory approval or commercial success.
- Regulatory and Pricing: Potential impacts from the Inflation Reduction Act (IRA) and new CMS pricing models (GLOBE, GUARD) could affect future pricing and reimbursement if products are approved.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $343.1 million cash balance against the projected burn rate to confirm the "into 2028" runway estimate.
- Supply Chain Mitigation: Assess the progress of identifying alternative API suppliers to mitigate the risk associated with the sole reliance on a WuXi AppTec affiliate.
- Clinical Data Validation: Monitor the upcoming 2026 data readouts for vopimetostat (pancreatic and lung cohorts) and the combination trial with Revolution Medicines to validate the path to a pivotal trial.
- Revenue Sustainability: Note that 2025 revenue included a one-time recognition of deferred revenue from the Gilead agreement truncation; future revenue will depend on new collaborations or product sales.
- Program Discontinuations: Review the impact of discontinuing TNG908 and TNG348 on the overall pipeline depth and resource allocation.